Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDAPTOMYCIN (daptomycin) by Pfizer is [see clinical pharmacology ()] . Approved for pneumonia, left-sided infective endocarditis due to s, skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates) and 12 more indications. First approved in 2014.
Drug data last refreshed 18h ago
[see Clinical Pharmacology ()] .
Worked on DAPTOMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo